High-Dose Ara-C Followed by Continuous Infusion Interleukin-2 for Acute Myelogenous Leukemia in First Remission
Patients will receive standard remission induction therapy with daunorubicin at a dose of 45
mg/m2/day for 3 days and continuous infusion cytarabine at a dose of 200 mg/m2/day for 7
Those patients who enter a remission status and have preserved liver and kidney function
will then receive 3 cycles of post-remission therapy that will consist of high-dose
cytarabine at a dose of 3000 mg/m2 every 12 (q12) hours on days 1, 3 and 5 (total of 6
Patients who are still in remission will receive interleukin-2 (IL-2) upon count recovery at
a dose of 8.1 X 10^5 U/m2/day by continuous infusion for 10 weeks. In addition, patients
will receive bolus IL-2 at a dose of 6 X 10^5 U/m2 by intravenous bolus weekly for 6 doses
through day 63.
Patients will be seen on a weekly basis while on treatment for examination and bloodwork.
At the end of treatment, patients will have a physical exam and bloodwork performed monthly
for two years, then 4 times per year for two years.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label
The primary purpose of this study is to evaluate the ability of IL-2 to generate cytotoxic and inhibitory activity against cryopreserved autologous leukemic myeloblasts obtained at the time of diagnosis.
Richard M. Stone, MD
Dana-Farber Cancer Institute
United States: Institutional Review Board
|Dana-Farber Cancer Institute||Boston, Massachusetts 02115|